Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis

Abstract Objective. Mucosal cytokine profile determines T cell differentiation and may play an important role in the clinical course of inflammatory bowel disease (IBD). Cytokines from different T helper (Th) cell subsets are elevated in inflamed mucosa of patients with ulcerative colitis (UC), contributing to the inflammation. The aim of this study was to determine the predictive value of pre-treatment mucosal cytokine profile in response to therapy with the anti-TNF agent infliximab (IFX). Material and methods. The expression of Th1, Th17, Th2 and T-regulatory (Treg)-related cytokines was quantified by real-time PCR in mucosal biopsies from 74 UC patients before initiation of IFX induction therapy. Clinical and endoscopic effects were assessed after three infusions. Remission was defined as ulcerative colitis disease activity index (UCDAI) below 3. Results. Higher gene expression levels of IL-17A and IFN-γ were significantly associated with remission after three IFX infusions (OR = 5.4, p = 0.013 and OR = 5.5, p = 0.011, respectively). IL-17A and IFN-γ mRNA expression showed positive correlation. Th2 and Treg-related mediators were not significantly associated with clinical outcome, but were expressed at higher levels in UC patients compared with the controls. Immunohistochemistry (IHC) confirmed the presence of cells expressing both IL-17A and IFN-γ. Conclusions. High expression of Th1- and Th17-related cytokines in the mucosa of UC patients can potentially predict a favorable outcome of IFX induction therapy. Th2 and Treg-related mediators do not appear useful as predictive markers.

[1]  L. Peyrin-Biroulet,et al.  Clinical implications of mucosal healing for the management of IBD , 2010, Nature Reviews Gastroenterology &Hepatology.

[2]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[3]  Richard A Flavell,et al.  A protective function for interleukin 17A in T cell–mediated intestinal inflammation , 2009, Nature Immunology.

[4]  B. Vonen,et al.  Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis , 2007, Scandinavian journal of gastroenterology.

[5]  D. Rampton,et al.  DIFFERENTIAL REGULATION OF INTERLEUKIN-17 AND INTERFERON- PRODUCTION IN INFLAMMATORY BOWEL DISEASE , 2011 .

[6]  V. Kuchroo,et al.  Interleukin-17 and type 17 helper T cells. , 2009, The New England journal of medicine.

[7]  T. Macdonald,et al.  Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. , 2005, Gastroenterology.

[8]  P. Mannon,et al.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. , 2004, The Journal of clinical investigation.

[9]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.

[10]  B. Vonen,et al.  Improvement of real‐time polymerase chain reaction for quantifying TNF‐α mRNA expression in inflamed colorectal mucosa: An approach to optimize procedures for clinical use , 2006, Scandinavian journal of clinical and laboratory investigation.

[11]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[12]  S. Brand,et al.  Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis , 2010, The American Journal of Gastroenterology.

[13]  G. Cui,et al.  TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. , 2011, Cytokine.

[14]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[15]  S. Steigen,et al.  Reduced expression of microenvironmental Th1 cytokines accompanies adenomas–carcinomas sequence of colorectum , 2007, Cancer Immunology, Immunotherapy.

[16]  Andreas Stallmach,et al.  Predictive value of mucosal TNF‐&agr; transcripts in steroid‐refractory Crohn's disease patients receiving intensive immunosuppressive therapy , 2007, Inflammatory bowel diseases.

[17]  B. Vainer,et al.  Upregulation of Interleukin-12 and -17 in Active Inflammatory Bowel Disease , 2003, Scandinavian journal of gastroenterology.

[18]  G. Cui,et al.  TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. , 2009, Cytokine.

[19]  G Van Assche,et al.  Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis , 2009, Gut.

[20]  L. Cosmi,et al.  Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.

[21]  Chen Dong,et al.  TH17 cells in development: an updated view of their molecular identity and genetic programming , 2008, Nature Reviews Immunology.

[22]  I. Fuss.  Is the Th1/Th2 paradigm of immune regulation applicable to IBD? , 2008, Inflammatory bowel diseases.

[23]  I. Dotan,et al.  Immunopathogenesis of inflammatory bowel disease , 2002, Current opinion in gastroenterology.

[24]  T. Hibi,et al.  IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease , 2008, Gut.

[25]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[26]  L. Mayer,et al.  Evolving paradigms in the pathogenesis of IBD , 2009, Journal of Gastroenterology.

[27]  Fuping Zhang,et al.  Proinflammatory cytokines underlying the inflammation of Crohn's disease , 2010, Current opinion in gastroenterology.

[28]  V. Kuchroo,et al.  TH-17 cells in the circle of immunity and autoimmunity , 2007, Nature Immunology.

[29]  G. Cui,et al.  Helicobacter pylori Stimulates a Mixed Adaptive Immune Response with a Strong T‐Regulatory Component in Human Gastric Mucosa , 2007, Helicobacter.

[30]  P. Rutgeerts,et al.  Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab† , 2010, Inflammatory bowel diseases.

[31]  S. Brand,et al.  Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL‐22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status , 2008, Inflammatory bowel diseases.

[32]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[33]  D. Littman,et al.  Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. , 2011, Gastroenterology.

[34]  W. Fries,et al.  Candidate mucosal and surrogate biomarkers of inflammatory bowel disease in the era of new technology , 2011, Scandinavian journal of gastroenterology.

[35]  A. Andoh,et al.  Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.

[36]  B. Sands.  From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. , 2004, Gastroenterology.

[37]  R. Sartor.  Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis , 2006, Nature Clinical Practice Gastroenterology &Hepatology.